[소셜밸류=박완규 기자] Biobytes officially announced the signing of Strategic Memorandum of Understanding (MOU and a Non-Disclosure Agreement (NDA) with the Myomar Molecular Inc, a Canadina MDx firm specializing in molecular diagnostics for sarcopenia to foster its expansion into the global market.
Biobytes specializes in discovering and developing new drug biomarkers utilizing sarcopenia biobank cohort data. Through its collaboration with Hyundai Engineering and Construction under the Seoul Startup Hub Gongdeok Open Innovation Support Program, the company strengthened its experience technology validation and commercialization with major enterprises. These efforts have demonstrated its technological edge and market scalability, establishing a solid foundation for forming global partnerships aligned with its global expansion strategy.
Through this partnership, Biobytes will leverage Sarco-Finding, its proprietary AI-driven analysis technology for blood and tissue data to analyze biospecimens from Myomar, introducing the next-generation solution for sarcopenia diagnostics and therapeutics.
The effort provides Biobytes an opportunity to scale up its world-first multicenter sarcopenia biobank cohort database Muscle Bank globally and produce meaningful clinical data accepted across global markets.
Lee Jung-woo, the CEO of Biobytes said,” Our partnership with Myomar is more than a mere technical collaboration. It marks an important turning point for setting global standards in the sarcopenia field. We are committed to advance this toward sarcopenia drug development by leveraging the sarcopenia patient data and analytical capabilities held by both companies.
Meanwhile, Biobytes has been well regarded for both is innovation and business potential across diverse areas, including AI-powered medical devices for assisting in sarcopenia diagnosis and health functional foods for muscle strength improvement. It is leading the market by providing sarcopenia risk assessments in under one minute.
Biobytes is creating the world’s first multicenter sarcopenia patient biobank cohort database working with medical institutions including Wonju Severance Christian Hospital, Kangbuk Samsung Hospital, and Seoul St. Mary’s Hospital. Using this database, the company has begun the technology transfer process for 10 novel sarcopenia drug biomarkers identified via its AI-powered biomarker discovery platform Sarco-Finding.
[저작권자ⓒ 사회가치 공유 언론-소셜밸류. 무단전재-재배포 금지]
